E D Michelakis

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. doi request reprint Emerging concepts and translational priorities in pulmonary arterial hypertension
    Evangelos D Michelakis
    Department of Medicine, Cardiology Division, Pulmonary Hypertension Program, University of Alberta, Edmonton, Alberta, Canada
    Circulation 118:1486-95. 2008
  2. pmc Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
    E D Michelakis
    Department of Medicine, University of Alberta, Edmonton, Canada
    Br J Cancer 99:989-94. 2008
  3. ncbi request reprint An evidence-based approach to the management of pulmonary arterial hypertension
    Stephen L Archer
    Vascular Biology Group, Division of Cardiology, Canada
    Curr Opin Cardiol 21:385-92. 2006
  4. ncbi request reprint Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells
    E D Michelakis
    Department of Medicine Cardiology, Walter C Mackenzie Health Sciences Center, University of Alberta, Edmonton, Alberta, Canada
    J Pharmacol Exp Ther 291:1143-9. 1999
  5. ncbi request reprint Potassium channels regulate tone in rat pulmonary veins
    E D Michelakis
    Department of Medicine Cardiology, University of Alberta, Edmonton, Alberta T6G 2B7, Canada
    Am J Physiol Lung Cell Mol Physiol 280:L1138-47. 2001
  6. doi request reprint Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer
    G Sutendra
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Oncogene 32:1638-50. 2013
  7. doi request reprint Metabolic modulation of glioblastoma with dichloroacetate
    E D Michelakis
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Sci Transl Med 2:31ra34. 2010
  8. ncbi request reprint Anorectic drugs and pulmonary hypertension from the bedside to the bench
    E D Michelakis
    Department of Medicine, University of Alberta, Edmonton, Canada
    Am J Med Sci 321:292-9. 2001
  9. ncbi request reprint The pathobiology of pulmonary hypertension. Smooth muscle cells and ion channels
    E D Michelakis
    Department of Medicine, Division of Cardiology, the Vascular Biology Group, University of Alberta, Edmonton, Canada
    Clin Chest Med 22:419-32. 2001
  10. ncbi request reprint Gene transfer and metabolic modulators as new therapies for pulmonary hypertension. Increasing expression and activity of potassium channels in rat and human models
    E D Michelakis
    Department of Medicine (Cardiology, University of Alberta, Edmonton, Canada
    Adv Exp Med Biol 502:401-18. 2001

Collaborators

  • M R Wilkins
  • E K Weir
  • S L Archer
  • S Wang
  • Marlene Rabinovitch
  • X Wu
  • B Thebaud
  • G Lopaschuk
  • G Thurston
  • Dario Altieri
  • M Sean McMurtry
  • Sebastien Bonnet
  • Rohit Moudgil
  • Alois Haromy
  • Sandra Bonnet
  • Kyoko Hashimoto
  • Gwyneth Harry
  • G Sutendra
  • Christopher J Porter
  • Lakshmi Puttagunta
  • Jason R B Dyck
  • Zlatko I Pozeg
  • A Kinnaird
  • M S McMurtry
  • J M R Parker
  • P Dromparis
  • T H Stenson
  • A Haromy
  • Linda Webster
  • Sandra N Bonnet
  • Miguel A Andrade
  • Joan Allalunis-Turner
  • Gael Rochefort
  • Christopher T Lee
  • Gopinath Sutendra
  • Christian Beaulieu
  • Richard Thompson
  • Miguel A Andrade-Navarro
  • Arvind Koshal
  • Richard Sultanian

Detail Information

Publications27

  1. doi request reprint Emerging concepts and translational priorities in pulmonary arterial hypertension
    Evangelos D Michelakis
    Department of Medicine, Cardiology Division, Pulmonary Hypertension Program, University of Alberta, Edmonton, Alberta, Canada
    Circulation 118:1486-95. 2008
  2. pmc Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
    E D Michelakis
    Department of Medicine, University of Alberta, Edmonton, Canada
    Br J Cancer 99:989-94. 2008
    ..Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials...
  3. ncbi request reprint An evidence-based approach to the management of pulmonary arterial hypertension
    Stephen L Archer
    Vascular Biology Group, Division of Cardiology, Canada
    Curr Opin Cardiol 21:385-92. 2006
    ..Evidence-based therapies and guidelines for pulmonary arterial hypertension are critiqued...
  4. ncbi request reprint Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells
    E D Michelakis
    Department of Medicine Cardiology, Walter C Mackenzie Health Sciences Center, University of Alberta, Edmonton, Alberta, Canada
    J Pharmacol Exp Ther 291:1143-9. 1999
    ..To our knowledge, this is the first time that a commonly prescribed drug with voltage-gated K(+) channel-blocking properties is shown to have significant hemodynamic effects in vivo...
  5. ncbi request reprint Potassium channels regulate tone in rat pulmonary veins
    E D Michelakis
    Department of Medicine Cardiology, University of Alberta, Edmonton, Alberta T6G 2B7, Canada
    Am J Physiol Lung Cell Mol Physiol 280:L1138-47. 2001
    ..We conclude that K(+) channels are present and functionally important in rat PVs. PVCMs form sphincters rich in K(ir) channels, which may modulate venous return both physiologically and in disease states including pulmonary edema...
  6. doi request reprint Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer
    G Sutendra
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Oncogene 32:1638-50. 2013
    ....
  7. doi request reprint Metabolic modulation of glioblastoma with dichloroacetate
    E D Michelakis
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Sci Transl Med 2:31ra34. 2010
    ..Metabolic modulation may be a viable therapeutic approach in the treatment of glioblastoma...
  8. ncbi request reprint Anorectic drugs and pulmonary hypertension from the bedside to the bench
    E D Michelakis
    Department of Medicine, University of Alberta, Edmonton, Canada
    Am J Med Sci 321:292-9. 2001
    ..One potentially beneficial effect of the epidemics of anorectic-related PPH is that it may have provided important insights into the causes of PPH unrelated to anorectic agents...
  9. ncbi request reprint The pathobiology of pulmonary hypertension. Smooth muscle cells and ion channels
    E D Michelakis
    Department of Medicine, Division of Cardiology, the Vascular Biology Group, University of Alberta, Edmonton, Canada
    Clin Chest Med 22:419-32. 2001
    ..The selective Kv1.5 down-regulation leaves wide open the door to replacement gene therapy in pulmonary hypertension research...
  10. ncbi request reprint Gene transfer and metabolic modulators as new therapies for pulmonary hypertension. Increasing expression and activity of potassium channels in rat and human models
    E D Michelakis
    Department of Medicine (Cardiology, University of Alberta, Edmonton, Canada
    Adv Exp Med Biol 502:401-18. 2001
    ..Adenoviral gene transfer increased expression of Kv2.1 channels and enhanced 4-AP constriction in human PAs. CONCLUSION: Increasing Kv channel function in PAs is feasible and might be beneficial...
  11. ncbi request reprint The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension
    Rohit Moudgil
    Vascular Biology Group, Division of Cardiology, University of Alberta, Edmonton, Canada
    Microcirculation 13:615-32. 2006
    ..In conclusion, K+ channels regulate pulmonary vascular tone and remodeling and constitute potential therapeutic targets in the regression of PAH...
  12. ncbi request reprint Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension
    M Sean McMurtry
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2B7
    Am J Physiol Lung Cell Mol Physiol 292:L872-8. 2007
    ..Depressed BMPR2 expression may be a marker of PAH but is not central to the pathogenesis of this model of PAH...
  13. ncbi request reprint A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth
    Sebastien Bonnet
    Pulmonary Hypertension Program and Vascular Biology Group, Department of Physiology, University of Alberta, Edmonton, AB T6G 2B7, Canada
    Cancer Cell 11:37-51. 2007
    ..Molecular inhibition of PDK2 by siRNA mimics DCA. The mitochondria-NFAT-Kv axis and PDK are important therapeutic targets in cancer; the orally available DCA is a promising selective anticancer agent...
  14. pmc The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted
    Sebastien Bonnet
    Pulmonary Hypertension Program, University of Alberta, Edmonton, AB, Canada IGG 2B7
    Proc Natl Acad Sci U S A 104:11418-23. 2007
    ..The generalized activation of NFAT in human and experimental PAH might regulate the ionic, mitochondrial, and inflammatory remodeling and be a therapeutic target and biomarker...
  15. ncbi request reprint Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study
    M Sean McMurtry
    Vascular Biology Group, University of Alberta, Edmonton, Ontario, Canada
    Am J Physiol Lung Cell Mol Physiol 293:L933-40. 2007
    ..These negative results should be considered as human trials with these agents are underway (simvastatin) or proposed (rapamycin)...
  16. pmc The metabolic basis of vascular oxygen sensing: diversity, compartmentalization, and lessons from cancer
    Evangelos D Michelakis
    Am J Physiol Heart Circ Physiol 295:H928-H930. 2008
  17. ncbi request reprint An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension
    Sebastien Bonnet
    Vascular Biology Group, Division of Cardiology, University of Alberta, Edmonton, Canada
    Circulation 113:2630-41. 2006
    ..The cause of pulmonary arterial hypertension (PAH) was investigated in humans and fawn hooded rats (FHR), a spontaneously pulmonary hypertensive strain...
  18. ncbi request reprint The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension
    Evangelos D Michelakis
    University of Alberta Hospitals, Walter C McKenzie Health Sciences Centre, Edmonton, Canada
    Heart Fail Rev 8:5-21. 2003
    ..It focuses on the role of recent therapies that target the NO pathway, including L-Arginine, inhaled NO, the phosphodiesterase inhibitor sildenafil and gene therapy...
  19. ncbi request reprint In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats
    Zlatko I Pozeg
    Vascular Biology Group, Cardiology, University of Alberta, Edmonton, Canada
    Circulation 107:2037-44. 2003
    ..CH decreases Kv channel current/expression and depolarizes and causes Ca2+ overload in PASMCs. We hypothesize that Kv gene transfer would normalize the pulmonary circulation (restore HPV and reduce CH-PHT), despite ongoing hypoxia...
  20. ncbi request reprint Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension
    Evangelos D Michelakis
    Vascular Biology Group and Pulmonary Hypertension Program, Department of Medicine, University of Alberta, 2C2 Walter C Mackenzie Health Sciences Centre, 8440 112th St, Edmonton, Alberta, Canada, T6G 2B7
    Circulation 108:2066-9. 2003
    ..However, the long-term effects of PD-5 inhibition and its mechanism of action in human pulmonary arteries (PAs) are unknown...
  21. ncbi request reprint The NO - K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies
    Evangelos D Michelakis
    University of Alberta Hospitals, 2C2 Walker C McKenzie Health Sciences, Centre, Edmonton, Canada
    Adv Exp Med Biol 543:293-322. 2003
    ..These drugs appear safe in humans and may be useful PAH therapies, alone or in combination...
  22. ncbi request reprint Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis
    M Sean McMurtry
    Department of Medicine and Pediatrics, University of Alberta, Edmonton, Canada
    Circ Res 95:830-40. 2004
    ..5 in the media. We identify mitochondria-dependent apoptosis as a potential target for therapy and DCA as an effective and selective treatment for PAH...
  23. ncbi request reprint Hypoxic pulmonary vasoconstriction
    Rohit Moudgil
    Cardiology Division, Dept of Medicine, and Vascular Biology Group, University of Alberta, WMC 2C2 36, 8440 112th Street, Edmonton, Alberta, Canada T6G 2B7
    J Appl Physiol 98:390-403. 2005
    ..HPV is clinically exploited in single-lung anesthesia, and its mechanisms intersect with those of pulmonary arterial hypertension...
  24. pmc Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension
    M Sean McMurtry
    The Vascular Biology Group and Pulmonary Hypertension Program, University of Alberta, Edmonton, Alberta, Canada
    J Clin Invest 115:1479-91. 2005
    ..Inhibition of the inappropriate expression of survivin that accompanies human and experimental PAH is a novel therapeutic strategy that acts by inducing vascular mitochondria-dependent apoptosis...
  25. ncbi request reprint Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels
    Evangelos D Michelakis
    Department of Medicine, University of Alberta, Edmonton, Canada
    Circulation 105:244-50. 2002
    ..We hypothesized that dichloroacetate (DCA), a metabolic modulator that can shift redox balance toward an oxidized state and increase Kv current in myocardial cells, would reverse CH-PHT...
  26. ncbi request reprint Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications
    Evangelos D Michelakis
    Circ Res 98:172-5. 2006
  27. ncbi request reprint Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization
    Bernard Thebaud
    Division of Neonatology, Department of Pediatrics, University of Alberta, Edmonton, Canada
    Circulation 112:2477-86. 2005
    ..Vascular endothelial growth factor (VEGF) is a trophic factor required for endothelial cell survival and is abundantly expressed in the lung...